Successful treatment and remission of advanced testicular cancer after COVID-19 infection during induction chemotherapy

Q4 Medicine IJU Case Reports Pub Date : 2024-05-01 DOI:10.1002/iju5.12726

Goshi Kitano, Shiori Tanaka, Manabu Kato, Naoya Itoh, Takahiro Kojima

{"title":"Successful treatment and remission of advanced testicular cancer after COVID-19 infection during induction chemotherapy","authors":"Goshi Kitano, Shiori Tanaka, Manabu Kato, Naoya Itoh, Takahiro Kojima","doi":"10.1002/iju5.12726","DOIUrl":null,"url":null,"abstract":"<div>\n \n <section>\n \n <h3> Introduction</h3>\n \n <p>We report a case of advanced testicular cancer cured by early and appropriate resumption of chemotherapy even after COVID-19 infection during induction chemotherapy.</p>\n </section>\n \n <section>\n \n <h3> Case presentation</h3>\n \n <p>The patient was a healthy 36-year-old male. The diagnosis was a stage IIIB nonseminoma (pT2N2M1a). On day 14 of the first chemotherapy cycle, the patient was diagnosed with mild COVID-19. The second chemotherapy cycle was initiated with a 1-day delay (on day 10 after the COVID-19 diagnosis). The patient achieved remission with minimal postponement of chemotherapy.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Only a few case reports have described the resumption of anticancer chemotherapy in patients with COVID-19. In deciding when to resume chemotherapy after COVID-19 infection, it is essential to consider factors such as cancer type, progression, and severity of COVID-19 and should be tailored to individual patient needs.</p>\n </section>\n </div>","PeriodicalId":52909,"journal":{"name":"IJU Case Reports","volume":"7 4","pages":"289-292"},"PeriodicalIF":0.0000,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/iju5.12726","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"IJU Case Reports","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/iju5.12726","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

We report a case of advanced testicular cancer cured by early and appropriate resumption of chemotherapy even after COVID-19 infection during induction chemotherapy.

Case presentation

The patient was a healthy 36-year-old male. The diagnosis was a stage IIIB nonseminoma (pT2N2M1a). On day 14 of the first chemotherapy cycle, the patient was diagnosed with mild COVID-19. The second chemotherapy cycle was initiated with a 1-day delay (on day 10 after the COVID-19 diagnosis). The patient achieved remission with minimal postponement of chemotherapy.

Conclusion

Only a few case reports have described the resumption of anticancer chemotherapy in patients with COVID-19. In deciding when to resume chemotherapy after COVID-19 infection, it is essential to consider factors such as cancer type, progression, and severity of COVID-19 and should be tailored to individual patient needs.

Abstract Image

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

诱导化疗期间感染 COVID-19 后成功治疗晚期睾丸癌并获得缓解

我们报告了一例晚期睾丸癌患者，即使在诱导化疗期间感染了COVID-19，也能通过早期适当恢复化疗而治愈。患者为 36 岁健康男性，诊断为 IIIB 期非睾丸癌（pT2N2M1a）。在第一个化疗周期的第14天，患者被诊断为轻度COVID-19感染。第二个化疗周期推迟了 1 天（在确诊 COVID-19 后的第 10 天）开始。只有少数病例报告描述了 COVID-19 患者恢复抗癌化疗的情况。在决定感染COVID-19后何时恢复化疗时，必须考虑癌症类型、进展情况和COVID-19的严重程度等因素，并应根据患者的个体需求而定。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊